Share Name Share Symbol Market Type Share ISIN Share Description
Glaxosmithkline Plc LSE:GSK London Ordinary Share GB0009252882 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -3.80 -0.25% 1,489.40 1,491.80 1,492.80 1,507.00 1,469.80 1,496.00 8,590,242 16:35:03
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 33,754.0 6,221.0 93.9 15.9 74,724

Glaxosmithkline Share Discussion Threads

Showing 19076 to 19100 of 21100 messages
Chat Pages: Latest  772  771  770  769  768  767  766  765  764  763  762  761  Older
DateSubjectAuthorDiscuss
04/2/2019
08:58
This feels like its been rangebound for ever and shows little sign of changing.Still better than constantly going down like some of my others (vod) !
tim 3
03/2/2019
11:52
Guessestimate the pre tax, apply a 20/22 multiple. That will take you somewhere near the figure, adjust for % ownership.
essentialinvestor
03/2/2019
10:38
Here's a project for someone good at numbers: GSK said it will hold a majority controlling interest in the new CH venture at 68 per cent, while Pfizer will retain an equity interest of the remaining 32 per cent. Within three years of closing the deal, GSK will break up the company into two separate businesses: one to be focused on consumer healthcare, and the other for pharmaceuticals and vaccines. It may also list the new venture in the UK. Once the value has been 'unlocked', can anyone speculate what the equivalent value would be to today's existing shareholders?
tradermichael
02/2/2019
09:30
Great tip for GSK today by Questor Daily Telegraph.
montyhedge
01/2/2019
17:19
My only hope is that we may unleash the animal instincts by demerging the company. Something akin to the old British Gas would be a success which I believe split three ways and all did prosper in time. BT also demerged into fixed line and mobile services. Maybe just maybe we have a giant that is finally awakening.
zicopele
01/2/2019
16:39
Yes, including dividends !
tradermichael
01/2/2019
16:24
patience has its rewards.
abdullla
01/2/2019
14:54
GSK has done nothing and gone nowhere for the last twenty years. The company is sclerotic. Even with the Pfizer deal and possible demerger, it has not budged. Very frustrating.....oh but we get the dividend...the gift which keeps giving blah blah but which is a noose around our necks.
zicopele
01/2/2019
11:31
Next quarterly dividend 23p.
montyhedge
01/2/2019
11:25
Erm ….. what year? Jan 2018 ~1300p Jan 2019 1400p = UP ~100p Jan 2019 ~1496p 1 Feb 2019 1486p = DOWN ~10p (INTRA DAY) ANNUAL DIVIDEND = 80P
tradermichael
01/2/2019
10:32
Oh dear....the dreaded dividend which is consuming shareholder value and promoting an approach of risk aversion to drug discovery. It will be cut and the share will fall. Already down by more than the annual dividend this year.
zicopele
01/2/2019
10:16
Yes steady income payers, dividend on the doormat every 13 weeks, that will do.
montyhedge
01/2/2019
09:58
Defensive stocks will be the key for making money in times of slowdown. GSK and AZN are the best and the safest on offer.
fuji99
31/1/2019
15:43
I know shareprice been disappointing, but out of all my shares, GSK and a small one S4 Capital are the best two, I'm excited about for the future.
montyhedge
31/1/2019
15:40
Results next week. Sales of Shingrix for 2018 are expected to be about $772 million in 2018 and peak at $4 billion. Another drug that is expected to do well is COPD drug Trelegy Ellipta. Sales are expected to hit about $2.2 billion.
tradermichael
31/1/2019
15:29
Yanks buying.
montyhedge
31/1/2019
14:37
Yanks selling.
montyhedge
31/1/2019
14:07
Thankfully governments are beginning to wake up to the antibiotic resistance crisis, all be it belatedly. Give the pharma companies whatever incentives they need, well with reason, to drive research in this area.
essentialinvestor
31/1/2019
13:58
Dr biotech...don't guess anything. What I dont want is a chief exec who is lauded for being female. I want someone who will increase the share price. Accusations of mysogonism for concerns expressed about Emma's lack of scientific background are a concern. She must be judged on results but is not beyond criticism simply for being female.
zicopele
31/1/2019
13:46
hTtps://uk.finance.yahoo.com/news/want-second-income-stream-ftse-124746113.html
fuji99
31/1/2019
13:46
Darwin came from apes?
abdullla
31/1/2019
13:42
Darwin studied medicine, before theology. Zico -Andrew Witty was an economics graduate. I am guessing that you don't like her because she is a woman. I have a PhD in analytical biochemistry, but whilst I understand the basics I would be unable to hold deep conversation about (most) areas of medical research. That would apply to just about anyone - its why you become an expert in your field. What she would need to know is the risk/benefit of any particular project. Unfortunately even having an indepth knowledge about a particular drug doesn't really help in understanding its chances of passing.
dr biotech
31/1/2019
13:35
GSk will return to dividend growth 2020.
montyhedge
31/1/2019
13:16
Zico, I don’t know EM personally, but your argument may not always be true. I am told that Charles Darwin’s degree was in Theology, but many scientists worship him!!( I am a scientist but I don’t).I knew Richard Sykes personally, and Andrew Witty slightly, but not Emma, although I am impressed by some of her decisions and arguments. GSK has not done well in the past few years so change was needed. She is definitely different, so let us give her a chance to perform.
jadeticl3
31/1/2019
13:07
She has surrounded herself with a team of scientific and business experts. That's the art of higher management.
tradermichael
Chat Pages: Latest  772  771  770  769  768  767  766  765  764  763  762  761  Older
ADVFN Advertorial
Your Recent History
LSE
GSK
Glaxosmith..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200405 06:13:08